There is no publicly available, independently verified net worth figure for François Maisonrouge as of June 3, 2026. He is a senior investment banker, not a celebrity or public company executive required to disclose personal wealth, so no credible aggregator has published a sourced estimate. What we can say with confidence: based on his career trajectory, compensation benchmarks for senior managing directors at elite boutique advisory firms, and decades of work on marquee healthcare M&A deals, his net worth likely falls somewhere in the range of $10 million to $50 million, and could be higher depending on carried interest, equity stakes, and personal investments accumulated over 30-plus years in the industry.
Francois Maisonrouge Net Worth 2026: Estimate, Sources, Details
Marcus Holloway
3 Jun 2026
Making sure we're talking about the right person
The surname Maisonrouge is uncommon but not unique, and search results can surface multiple people. The most prominent historical Maisonrouge in business circles is Jacques Maisonrouge, a French executive who ran IBM World Trade Corporation. He is not the person this article covers. There is also Ketty Pucci-Sisti Maisonrouge, a Columbia Business School figure, who appears in searches and is connected to François Jacques Maisonrouge as a spouse, per biographical records. She is also not the subject here.
The person you are most likely searching for is François J. Maisonrouge (CRD# 1284055 on FINRA BrokerCheck), a French-born investment banker based in New York. He is consistently identified across Evercore's team page, FINRA registration records, a 2007 Evercore press release, and third-party professional directories as a Senior Managing Director at Evercore and chairman of the firm's Global Healthcare Group. The accent variant François (with the cedilla) and the unaccented Francois are both used in different sources and refer to the same individual.
What François Maisonrouge actually does for a living
Maisonrouge is a healthcare investment banker, specifically a senior advisor on large-scale mergers, acquisitions, and capital-raising transactions in the pharmaceutical, biotech, and life sciences sectors. His career splits into two long chapters. The first was nearly 15 years at Credit Suisse, where he rose to Managing Director and Chairman of Life Sciences. His client list there included some of the largest names in global pharma: Johnson & Johnson, Schering-Plough, Wyeth, GlaxoSmithKline, Roche, and Teva. That is the kind of client roster that generates significant deal fees over time.
In May 2007, he joined Evercore Partners as a Senior Managing Director, a move announced via a formal press release. At Evercore, he has been the lead banker on a string of landmark healthcare deals, including advising AstraZeneca on its acquisition of Alexion, BMS on Celgene, Takeda on Shire, Sanofi on Principia, Nestlé on the sale of Nestlé Skin Health to EQT and ADIA, and AstraZeneca during its high-profile defense against Pfizer's takeover attempt. These are billion-dollar and multi-billion-dollar transactions. Each one generates advisory fees that flow partly to the firm and partly, in various forms, to the senior bankers responsible.
Outside of pure deal-making, he sits on the Board of Advisors of the Harvard Business School Health Care Initiative, serves as chairman of the Pasteur Foundation (including as President of Pasteur Foundation Inc., per IRS 990 filings), and has been a speaker at institutions including the Collège de France. In 2014, he was awarded the rank of Chevalier de la Légion d'Honneur, France's highest civil honor, a recognition that reflects both his professional standing and his contributions to French-American institutional ties.
Net worth estimate as of June 2026
No major net worth aggregator has published a figure for François Maisonrouge. His wealth profile simply does not appear in the standard databases that cover entertainers, athletes, or celebrity executives. This is typical for senior investment bankers who are not founders of publicly traded firms and have not made headlines for personal wealth disclosures. The absence of a listed figure does not mean his net worth is negligible. It means his wealth is private, as is standard for this class of professional.
Based on compensation benchmarks for Senior Managing Directors at elite boutique advisory firms like Evercore, combined with the scale and frequency of the transactions he has led, a reasonable estimated range is $10 million to $50 million, with the realistic midpoint probably sitting closer to $20 million to $30 million. If he has accumulated meaningful equity in Evercore or its predecessor entities, or has significant personal investment portfolios built over three decades of high earnings, the upper bound could exceed $50 million. This is an informed estimate built on career evidence, not a sourced figure, and it should be treated accordingly.
How this estimate is built: sources and methodology
When there is no direct net worth disclosure, the methodology relies on four types of evidence: career tenure and seniority, industry compensation benchmarks, the scale of deals worked on, and any publicly visible assets or disclosures (real estate, SEC filings, nonprofit 990s). For Maisonrouge, all four are limited in their directness but collectively useful.
- Career tenure: roughly 15 years at Credit Suisse (approximately 1992 to 2007) at Managing Director and Chairman level, followed by 17-plus years at Evercore as Senior Managing Director. That is over 30 years of senior-tier compensation.
- Industry benchmarks: Senior Managing Directors at bulge-bracket and elite boutique banks typically earn $2 million to $10 million annually in total compensation (salary plus bonus), with deal-specific bonuses on large transactions pushing that higher in active years.
- Deal scale: The transactions Maisonrouge is credited with advising on (Takeda/Shire was roughly $62 billion; BMS/Celgene was $74 billion; AstraZeneca/Alexion was $39 billion) generate advisory fees in the tens to hundreds of millions of dollars at the firm level. Senior advisors capture a portion of that.
- Nonprofit 990 data: IRS records list him as President of Pasteur Foundation Inc., which confirms civic involvement but does not provide personal financial data.
- No real estate records, SEC insider disclosures, or wealth declarations were surfaced in research, which is consistent with a private individual not running a public company.
The wealth-building timeline: how his net worth likely grew
The earnings trajectory for someone in Maisonrouge's position follows a fairly predictable arc, even if the exact numbers are private. The early Credit Suisse years in the 1990s would have built the foundation, starting with analyst and associate-level compensation and scaling up through the ranks. By the time he was Chairman of Life Sciences, his annual package was almost certainly in the multi-million dollar range, with significant bonuses tied to deals closed for clients like Johnson & Johnson and Roche.
The move to Evercore in 2007 is the key inflection point. Elite boutique advisory firms like Evercore typically offer senior hires a combination of cash compensation and equity in the firm. Evercore went public in 2006, just before Maisonrouge joined, which means any equity granted around his 2007 start date would have appreciated substantially as Evercore's stock grew from a small boutique to a major independent advisory powerhouse. If he received Evercore equity as part of his compensation package, that alone could represent a significant portion of his net worth.
Since 2007, the deals he has been credited with are among the largest in healthcare M&A. Each completed mega-deal adds to both his professional reputation and his bonus compensation. The Chevalier de la Légion d'Honneur in 2014 marks roughly the midpoint of his Evercore tenure and reflects a career already at the top tier of the profession. His additional board roles, including the HBS Healthcare Initiative and the Pasteur Foundation, are unpaid or nominally compensated but signal the kind of professional network that generates ongoing deal flow.
How his wealth compares to peers in investment banking and finance
To put the estimate in context, it helps to look at where senior investment bankers sit relative to other high-earning professionals. Maisonrouge occupies the upper tier of private-wealth professionals but is not in the same category as firm founders or hedge fund principals who accumulate wealth through ownership and carried interest at scale.
| Professional Type | Typical Net Worth Range | Primary Wealth Source |
|---|---|---|
| Senior MD at elite boutique (non-founder) | $10M – $50M | Annual comp, firm equity grants |
| Investment bank founder/CEO (public firm) | $100M – $500M+ | Equity ownership, dividends |
| Hedge fund principal | $50M – $1B+ | Performance fees, capital appreciation |
| Private equity partner | $20M – $200M+ | Carried interest, deal returns |
| François Maisonrouge (estimated) | $10M – $50M | Advisory fees, Evercore equity, investments |
Within the site's coverage of French and Franco-named public figures, Maisonrouge sits in a different wealth bracket from entertainers and athletes. Actors like François Civil and François Cluzet, for example, built their wealth through film and television residuals, talent fees, and brand deals. For a similar “celebrity net worth” style inquiry, the François Civil net worth question is handled separately, since his sources and wealth drivers differ. Entrepreneurs covered elsewhere in this silo, like François Nader, accumulated wealth through biotech executive compensation, equity stakes, and company exits. If you are also searching for François Nader net worth, the key is to compare how each person’s earnings sources differ across their respective roles. Maisonrouge's wealth is built on fee-based advisory work and tenure at a prestigious firm, which is steady and substantial but rarely produces the headline-grabbing numbers associated with founder equity or entertainment royalties.
What to watch out for, and how to verify
The most common mistake people make when searching for net worth data on someone like François Maisonrouge is landing on auto-generated "celebrity net worth" pages that fabricate or wildly extrapolate figures without any sourcing. If a page claims to know his net worth to the dollar without citing any primary source, treat it with serious skepticism. No credible aggregator has published a sourced estimate for this individual as of this writing.
A second common error is conflating him with Jacques Maisonrouge, the IBM World Trade Corporation executive, or with other Maisonrouge family members who appear in academic and professional directories. Wikipedia documents a different individual, “Jacques Maisonrouge,” a French businessman who held executive roles at IBM World Trade Corporation, illustrating why the name requires disambiguation blank" rel="noopener noreferrer">conflating him with Jacques Maisonrouge, the IBM World Trade Corporation executive. The FINRA BrokerCheck entry (CRD# 1284055) is the most reliable disambiguation tool if you want to confirm you are looking at the right person.
If you want to track changes over time, the most useful signals to watch are Evercore's proxy statements and insider trading disclosures (since Evercore is publicly traded as EVR), which can show if registered insiders hold or sell shares. Maisonrouge himself may not appear in SEC filings as a named insider depending on his ownership threshold, but Evercore's annual reports do describe compensation structures for senior bankers. IRS 990 filings for Pasteur Foundation Inc. are publicly accessible and will continue to list officer information. None of these sources will give you a personal net worth number, but they provide the kind of grounded, verifiable data that makes any estimate more credible.
The bottom line: François Maisonrouge is a genuinely accomplished and well-compensated investment banker with a career spanning more than 30 years at the top of healthcare M&A advisory. His wealth is real, private, and substantial by most standards. His wealth is real, private, and substantial by most standards francois larpin net worth. The honest answer to the net worth question is a range of roughly $10 million to $50 million, built on decades of high-level deal work, and it could be higher. As of 2026, published sources still do not provide a confirmed, sourced François Leroux net worth figure, so any number you see online should be treated as speculation unless it cites primary documentation. Anyone claiming a precise figure without a sourced disclosure is guessing.
FAQ
How can I tell if an online “François Maisonrouge net worth” number is trustworthy?
Check for a primary basis (for example, SEC compensation or insider transaction reporting, or verified disclosures tied to equity holdings). If the page gives a single exact dollar figure without pointing to a primary document or a clearly described method, treat it as speculation, especially since this type of information is typically private for senior bankers.
Are François (with cedilla) and Francois (without) different people?
In practice, they are used interchangeably across sources, but you should still confirm identity using disambiguators. FINRA BrokerCheck (CRD# 1284055) is the cleanest way to verify you are looking at the right banker rather than a namesake.
What parts of an investment banker’s wealth can be estimated even without a public net worth figure?
You can often triangulate the “wealth drivers” like equity in the firm, long-tenure compensation patterns, and board or foundation-linked roles. For a public firm like Evercore, proxy statement compensation tables and insider share activity can help you gauge the direction of ownership even if they do not reveal personal net worth.
Could his net worth fall outside the $10 million to $50 million range?
Yes. If he received substantial equity that appreciated materially, his personal wealth could exceed the upper bound. Conversely, if he had lower equity grants, significant outside obligations, or limited investment upside, it could land at the low end. The point is that the range depends on equity and investment outcomes, which are not fully observable.
Does working on big healthcare deals automatically mean higher personal wealth?
Not automatically. Advisory fees flow mainly to the firm, and individual bankers’ take-home depends on seniority, deal credit allocation, bonus formulas, and equity participation. Two senior managing directors on the same transaction can have different total compensation depending on role, tenure, and firm compensation structure that year.
How do Evercore public filings help, if they rarely list personal net worth?
They can provide compensation structure and, in some cases, details about equity awards or stock ownership patterns for “named executive officers” and other insiders. If you see a pattern of selling or holding stock in insider trading disclosures, it can indicate whether ownership is likely growing or shrinking, which is relevant to wealth direction.
What if I see his name tied to Pasteur Foundation material, does that change net worth?
Board or advisory roles at nonprofits usually do not imply large personal wealth by themselves, because many are unpaid or modestly compensated. Still, IRS 990 filings can confirm identity, titles, and roles, which helps prevent misattribution when someone searches a name and lands on the wrong person.
Why do “auto-generated” net worth sites get this wrong so often for professionals like him?
They commonly use generic ranges, inflate incomes, or extrapolate from unrelated celebrities and founders. For a non-founder, fee-based senior banker, a fabricated “precise” number without primary support is especially unreliable, since the key asset driver is usually private personal balance sheet information.
Where should I look if I want the most grounded estimate update over time?
Monitor changes in publicly available compensation disclosures from Evercore (proxy statements, annual reports) and any insider transaction entries (for sale or buy patterns). For nonprofit-linked roles, track IRS 990 updates to maintain correct identity, even though it will not directly yield a net worth number.
